Finding ways to level up what people globally pay for drugs would not just ease the financial pressure American patients currently face. It could also fund a new wave of drug discovery and development to the benefit of all humanity.
Drug maker Bristol Myers Squibb just announced plans to sell its new schizophrenia drug Cobenfy at the same price in both the United Kingdom and the United States.
And if the British government refuses, the manufacturer may walk away from the market.
The drug maker’s posture portends good news for American patients.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.
When Drug Firms Stand Up to Price Controls, U.S. Patients Win
Sally C. Pipes
Finding ways to level up what people globally pay for drugs would not just ease the financial pressure American patients currently face. It could also fund a new wave of drug discovery and development to the benefit of all humanity.
Drug maker Bristol Myers Squibb just announced plans to sell its new schizophrenia drug Cobenfy at the same price in both the United Kingdom and the United States.
And if the British government refuses, the manufacturer may walk away from the market.
The drug maker’s posture portends good news for American patients.
Read the op-ed here.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.